PBAC Public Summary Documents – November 2021
Page last updated: 11 October 2022
Public Summary Documents relating to the November 2021 PBAC meeting.
- Acalabrutinib: Capsule 100 mg; Calquence®
- Adalimumab: Injection 40 mg in 0.8 mL pre-filled pen, Injection 40 mg in 0.8 mL pre-filled syringe; Hulio®
- Adalimumab: Injection 80 mg in 0.8 mL pre-filled syringe; Humira®
- Amifampridine: Tablet 10 mg; Ruzurgi®
- Apalutamide (m0CRPC): Tablet 60 mg; Erlyand®
- Apalutamide (mHSPC): Tablet 60 mg; Erlyand®
- Avalglucosidase alfa: Powder for injection 100 mg in 10 mL; Nexviazyme®
- Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Abevmy®
- Budesonide: Tablet (orally disintegrating) 0.5 mg Tablet (orally disintegrating) 1 mg; Jorveza®
- Buprenorphine: Injection (modified release) 8 mg in 0.16 mL pre-filled syringe, Injection (modified release) 16 mg in 0.32 mL pre-filled syringe, Injection (modified release) 24 mg in 0.48 mL pre-filled syringe, Injection (modified release) 32 mg in 0.64 mL pre-filled syringe; Buvidal® Weekly; Injection (modified release) 64 mg in 0.18 mL pre-filled syringe, Injection (modified release) 96 mg in 0.27 mL pre-filled syringe, Injection (modified release) 128 mg in 0.36 mL pre-filled syringe, Injection (modified release) 160 mg in 0.45 mL pre-filled syringe; Buvidal® Monthly
- Cabotegravir, cabotegravir and rilpivirine: Tablet containing cabotegravir 30 mg; Vocabria®; Pack containing 1 injection of cabotegravir 600 mg in 3 mL and 1 injection of rilpivirine 900 mg in 3 mL; Cabenuva®
- Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
- Cladribine: Tablet 10 mg; Mavenclad®
- Continued Dispensing Arrangements
- Dapagliflozin: Tablet 10 mg; Forxiga®
- Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC®
- Eculizumab: Solution concentrate for I.V. infusion 300 mg in 30 mL; Soliris®
- Empagliflozin: Tablet 10 mg; Jardiance®
- Essential amino acids formula with vitamins and minerals: Sachets containing oral powder 12.5 g, 50; EAA Supplement®
- Etanercept: Injections 50 mg in 1 mL single use pre-filled syringes, 4; Rymti®
- Fluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses; Trelegy Ellipta 200/62.5/25®
- Follitropin alfa: Injection 300 I.U. in 0.5 mL multi-dose cartridge, Injection 450 I.U. in 0.75 mL multi-dose cartridge, Injection 900 I.U. in 1.5 mL multi-dose cartridge; Gonal-f Pen®
- Gemtuzumab ozogamicin: Powder for Injection 5 mg; Mylotarg®
- Gilteritinib: Tablet 40 mg (as fumarate); Xospata®
- Imatinib: Tablet 600 mg; Imatab®
- Insulin aspart: Injections (human analogue), catridges, 100 units per mL, 3 mL, 5; Truvelog®; Injections (human analogue), pre-filled pen, 100 units per mL, 3 mL, 5; Truvelog Solostar®
- Ixekizumab: Injection 80 mg in 1 mL single dose pre-filled pen; Taltz®
- Larotrectinib: Capsule 25 mg, Capsule 100 mg, Oral solution 20 mg per mL, 100 mL; Vitrakvi®
- Mecasermin: Solution for injection 40 mg in 4 mL vial; Increlex®
- Mepolizumab: Injection 100 mg in 1 mL single dose pre-filled pen; Nucala®
- Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
- Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
- Omalizumab : Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe; Xolair®
- Pembrolizumab (OAC): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pembrolizumab (SCCHN): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Pneumococcal Polysaccharide Conjugate Vaccine, 15 Valent Adsorbed: 0.5 mL in pre-filled syringe; Trade name TBC
- Polyethylene glycol 400 with propylene glycol: Eye drops 4mg-3mg per mL, single dose units 0.8 mL, 30; Systane®
- Pregabalin: Oral solution 20 mg per mL, 473 mL; Pregabalin-AFT®
- Pregabalin: Tablet 82.5 mg, Tablet 165 mg, Tablet 330 mg; Lyrica CR®
- Progesterone: Pessary 200 mg; Oripro®
- Regorafenib: Tablet 40 mg (as monohydrate); Stivarga®
- Risankizumab: Injection 150mg in 1 mL pre-filled pen, Injection 150mg in 1 mL pre-filled syringe; Skyrizi®
- Rituximab: Solution for I.V. infusion 100 mg in 10 mL, Solution for I.V. infusion 500 mg in 50 mL; Ruxience®
- Sacituzumab govitecan: Powder for injection 180 mg; Trodelvy®
- Secukinumab: Injection 75 mg in 0.5 mL pre-filled syringe, Injection 150 mg in 1 mL pre-filled pen, Injection 300 mg in 2 mL pre-filled pen, Injection 300 mg in 2 mL pre-filled syringe; Cosentyx®
- Siltuximab: Powder for injection 100 mg, Powder for injection 400 mg; Sylvant®
- Tepotinib: Tablet 225 mg (as hydrochloride monohydrate); Tepmetko®
- Trastuzumab: Powder for I.V. infusion 440 mg; Herzuma®
- Trientine: Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine); Waymade®
- Trientine: Tablet 150 mg (as tetrahydrochloride); Cuprior®
The following Public Summary Documents have been updated:
July 2021 PBAC meeting
- Melatonin: Tablet 1 mg, Tablet 5 mg; Slenyto®
- Lorlatinib: Tablet 25 mg, Tablet 100 mg; Lorviqua®
- Dapagliflozin (chronic kidney disease): Tablet 10 mg; Forxiga®
